期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨髓增生异常综合征研究进展：第56届美国血液学会年会报道 被引量：2

Recent progress of myelodysplastic syndrome： reports from the 56th American Society of Hematology annual meeting
原文传递
导出
摘要 第56届美国血液学会（ASH）年会上关于骨髓增生异常综合征（MDS）的报道中有大量对发病机制的研究,现主要就ASH会议对MDS基因突变的报告进行介绍. The myelodysplastic syndrome （MDS）,which are characterized by the presence of ineffective hematopoetic stem cells.Research on pathogenesis and related epigetics has made significant progress in recent years,more and more abnormal cytogenetics and gene mutations are used for prognosis and treatment options for MDS.In the 56th American Society of Hematology （ASH） annual meeting,lots of gene mutations were introduced.
作者 孙谕 傅晋翔
机构地区 苏州大学附属第二医院血液科
出处 《白血病．淋巴瘤》 CAS 2015年第5期257-260,共4页 Journal of Leukemia & Lymphoma
关键词 骨髓增生异常综合征 发病机制 基因突变 美国血液学会年会 Myelodysplastic syndrome Pathogenesis Gene mutations American Society of Hematology annual meeting
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献22

  • 1Paloma 1, Andres I, Sonia G, et al. Prognostic value of chromosome 1 abnormalities in myelodysplastic syndrome [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 3240.
  • 2Heba A, Joop G, Austin K, et al. RPL27A is a target for Mir-595 and contributes to myelodysplastic phenotype through ribosomal dysgenesis [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 1895.
  • 3Valeria V, Ali T, John B, et al. Somatic mutations of the breast cancer amplified sequence-1 ( BCASI ), a novel leukemogenic driver in myelodysplastic syndromes with Del ( 20q ) [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 3250.
  • 4Tuoen Liu, Kilannin K, Cara L, et al.Knockdown of HSPA9 induces apoptosis and increases TP53 levels in human CD34+ hematopoietic progenitor cells [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124(21 ) : 526.
  • 5Jeffrey C, Joanna W, Rawa I, et al. Loss of MiR-143 and MiR-145 inhibits hematopoietic stem cell self-renewal through dysregulated TGF 13 signaling [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124(21 ) : 527.
  • 6David MR, Monica S, Emily H, et al. A proteomics screen identifies MDM2 binding partners specific to ribosomal protein haploinsuffieiency [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 1597.
  • 7Rebekka KS, Marie EM, Lisa PC, et al.Reduced protein synthesis and p53 activation in late-stage erythroblasts mediate the erythroid differentiation defect in mice with ribosomal protein S14 haploinsufficiency [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124(21 ) : 1892.
  • 8Rawa I, Joanna W, Linda Y, et al. Activation of non-canonical immune signalling pathways drives marrow failure in a murine model of MDS [J]. Blood (ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 3246.
  • 9Yang M, Baobing Z, Jing Y, et al. Loss of mDial mediates the development of Del ( 5q ) MDS through upregulation of the innate immune response and induction of neutropenia [ J ]. Blood ( ASH annual meeting abstracts ) , 2014, 124 ( 21 ) : 4617.
  • 10Hideki M, Keniehi Y, Thomas L, et al. In analogy to AML, MDS can be sub-classified by ancestral mutations [ J ]. Blood ( ASH annual meeting abstracts ), 2014, 124 ( 21 ) : 823.

同被引文献41

  • 1Papaemma nuil E, Gerstung M, Malcovali L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes[J].Blood, 2013, 122( 22 ) : 3616-3627; quiz 3699. DOI : 10.1182/blood-2013-08-518886.
  • 2Aul C, Galtermann N, Schneider W. Age-relaled incidence and other epidemiological aspects of myelodysplastic syndromes [J]. Br J Haematol, 1992, 82(2): 358-367.
  • 3Heaney ML, Golde DW. Myelodysplasia [J]. N Engl J Med, 1999, 340(21 ) : 1649-1660. DOI: 10.1056/NEJM199905273402107.
  • 4Yoshida K, Sanada M, Shiraishi Y, et al. Frequent palhway mutations of splicing machinery in myelodysplasia[J]. Nalure, 20l 1, 478( 7367 ) : 64-69. DOI : 10.1038/nature10496.
  • 5Dolatshad H, Pellagatti A, Fernandez-Mercado M, et ah Disruption of SF3BI results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenilor cells[J]. Leukemia, 2015, 29(5 ) : 1092-1103.
  • 6Lin CC, Hou HA, Chou WC, et al. SF3B1 mutations in patients with myelodysplastic syndromes: the mutalion is stable during diseaseevolution[J]. Am J Hematol, 2014, 89 (8): E109-115. DOI: 10.1002/ajh.23734.
  • 7Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value[J]. Blood, 2012, 119(2): 569-572. DOI : 10.1182/blood-2011-09-377994.
  • 8Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes[J].Blood, 2012, 120(16) : 3173-3186. DOI: 10.1182/blood-2012- 05-430876.
  • 9Haferlaeh T, Nagala Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes [J].Leukemia, 2014, 28(2): 241-247. DOI: 10.1038/leu.2013.336.
  • 10Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression [ J ]. Biochem J, 2009, 417 ( 1 ) : 15-27. DOI: 10.1042/BJ20081501.

引证文献2

二级引证文献3

白血病．淋巴瘤
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部